...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >Single‐dose local administration of teriparatide with a octacalcium phosphate collagen composite enhances bone regeneration in a rodent critical‐sized calvarial defect
【24h】

Single‐dose local administration of teriparatide with a octacalcium phosphate collagen composite enhances bone regeneration in a rodent critical‐sized calvarial defect

机译：用磷酸叔钯胶原复合材料的单剂量局部施用Triparatide，增强了啮齿动物临界大小的颅骨缺损中的骨再生

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Octacalcium phosphate and collagen composite (OCP/Col) achieves stable bone regeneration without cell transplantation in preclinical studies. Recently, a sponsor‐initiated clinical trial was conducted to commercialize the material. The present study investigated bone regeneration by OCP/Col with the single local administration of teriparatide (parathyroid hormone 1‐34; TPTD). OCP/Col was prepared by mixing sieved granules of OCP and atelocollagen for medical use and a disk was molded. After the creation of a rodent critical‐sized calvarial defect, OCP/Col or OCP/Col with dripped TPTD solution (1.0 or 0.1 μg; OCP/Col/TPTDd1.0 or OCP/Col/TPTDd0.1) was implanted into the defect. Six defects in each group were fixed 12 weeks after implantation. Radiographic examinations indicated that radiopaque figures in defects treated with OCP/Col with TPTD (OCP/Col/TPTDd) occupied a wider range than those treated with OCP/Col. Histological results demonstrated that most of the defect in OCP/Col/TPTDd was filled with newly formed bone. A histomorphometrical examination indicated that the percentage of newly formed bone was significantly higher in the defects of OCP/Col/TPTDd 1.0 (53.6?±?4.3%) and OCP/Col/TPTDd 0.1 (52.2?±?7.4%) than in those of OCP/Col (40.1?±?8.4%), whereas no significant differences were observed between OCP/Col/TPTDd1.0 and OCP/Col/TPTDd0.1. These results suggest that OCP/Col with the single local administration of TPTD enhances bone regeneration in a rodent calvarial critical‐sized bone defect. ? 2017 The Authors Journal of Biomedical Materials Research Part B: Applied Biomaterials Published by Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1851–1857, 2018.
机译：摘要在临床前研究中，八磷酸钙-胶原复合材料（OCP/Col）无需细胞移植即可实现稳定的骨再生。最近，发起人发起了一项临床试验，将该材料商业化。本研究调查了OCP/Col单次局部给药特立帕肽（甲状旁腺激素1-34；TPTD）后的骨再生。OCP/Col是通过混合OCP和阿替乐胶原的筛分颗粒制备的，用于医疗用途，并成型一个圆盘。在创建啮齿动物临界大小的颅骨缺损后，将OCP/Col或OCP/Col与滴入的TPTD溶液（1.0或0.1μg；OCP/Col/TPTDd1.0或OCP/Col/TPTDd0.1）植入缺损处。植入12周后，每组修复6处缺损。放射学检查表明，用OCP/Col和TPTD（OCP/Col/TPTDd）处理的缺损的不透射线图像比用OCP/Col处理的缺损的范围更广。组织学结果表明，OCP/Col/TPTDd中的大部分缺损由新生骨填充。组织形态计量学检查显示，OCP/Col/TPTDd 1.0（53.6±4.3%）和OCP/Col/TPTDd 0.1（52.2±7.4%）的骨缺损中新生骨的百分比显著高于OCP/Col（40.1±8.4%），而OCP/Col/TPTDd1之间无显著差异。0和OCP/Col/TPTDd0。1.这些结果表明，OCP/Col与TPTD的单一局部给药可促进啮齿动物颅骨临界大小骨缺损的骨再生？2017年《生物医学材料研究作者杂志》B部分：威利期刊有限公司出版的应用生物材料J Biomed Mater Res B部分：Appl Biometer，106B:1851–1857，2018年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号